1. Novartis Acquires Excellergy in $2 Billion Deal to Expand Allergy Drug Portfolio
Novartis is making a major strategic move into the allergy treatment market, agreeing to acquire Excellergy for a deal valued at up to $2 billion. This acquisition represents a significant bet on the growth potential of the allergy and immunology sector, as Novartis seeks to bolster its pipeline with Excellergy's speci...